Moderate coffee consumption—2 to 3 cups per day—was found to reduce the risk of multiple cardiometabolic diseases, including type 2 diabetes, cardiovascular disease, and stroke, by up to 20%. Those who consumed 200 to 300 mg of caffeine per day had a 48.1% or 40.7% reduced risk, respectively, for new onset cardiometabolic multimorbidity. The study, presented at the Endocrine Society’s 2024 conference, revealed that the bioactive compounds in coffee, such as polyphenols and diterpenes, play a vital role in improving insulin sensitivity and reducing chronic inflammation, which are critical in preventing metabolic diseases. 

A key finding of the prospective study of over 360,000 participants: regular coffee consumption improved markers of insulin sensitivity, helping regulate blood glucose levels more effectively. This effect is due primarily to chlorogenic acid, a potent polyphenol in coffee, which inhibits glucose absorption in the intestine and promotes insulin secretion. The study also noted a reduction in circulating pro-inflammatory cytokines, which in turn reduce exacerbating metabolic conditions. The coffee drinkers showed enhanced endothelial function, which supports cardiovascular health by preventing arterial stiffness and reducing the risk of atherosclerosis. Caffeine and polyphenols improve nitric oxide bioavailability, promoting vasodilation and improving blood flow. Notably, those participants who drank organic coffee showed even more pronounced benefits, likely due to the absence of pesticide residues. 

This study underscores the potential of moderate coffee consumption as a preventive measure for cardiometabolic diseases, particularly through its effects on insulin metabolism and inflammation. These findings suggest that when consumed regularly and in moderation, coffee can be part of a proactive strategy to reduce the risk of severe metabolic and cardiovascular conditions.